Biochemical and Biophysical Research Communications
Interleukin-6 (IL-6) mediates protection against glucose toxicity in human Müller cells via activation of VEGF-A signaling
Graphical abstract
Introduction
Neovascularization and retinal edema are two vision threatening complications for patients with diabetic retinopathy (DR). The current treatment strategy of choice for these patients is anti-VEGF therapy; however, this therapy is not reliable and is only effective for a small portion of the patient population [1]. Since the diabetic population is steadily rising, there is a pressing need for additional and more reliable therapies.
Recently, interleukin-6 has risen to the forefront as a target for drug development either as an anti-IL-6 therapy alone or in combination with anti-VEGF-A therapy. IL-6 is a pleiotropic cytokine known to participate in both acute and chronic inflammatory events. Its effects are dependent on microenvironment, cell type, and receptor expression [2]. Depending on which receptors are being expressed IL-6 can have beneficial or detrimental actions. The diverse effects of IL-6 are potentially due to activation of different IL-6 signaling pathways: classical IL-6 signaling and IL-6 trans-signaling. Classical IL-6 signaling, originally thought to be a protective pathway, is mediated by the binding of IL-6 to the membrane-bound IL-6 receptor (mIL-6R) and its association with membrane-bound glycoprotein 130 (gp130). On the other hand, IL-6 trans-signaling, which is has been suggested to be more pro-inflammatory in nature, is mediated by IL-6 binding to the soluble form of the IL-6 receptor (sIL-6R) and forming the IL-6/sIL-6R complex. This complex then interacts with gp130 to promote downstream signaling [[3], [4], [5]].
In the retina, IL-6 has been shown to be protective with regards to the neuroretina. Previous studies have shown that IL-6 is a key player in protecting photoreceptors from retinal detachment-induced cell death, retinal ganglion cells from pressure-induced cell death, and retinal Müller cells from high glucose-induced cell death [[6], [7], [8]]. In contrast, detrimental outcomes linked with IL-6, such as retinal barrier disruption, have been associated with the retinal vasculature [[9], [10], [11], [12]]. However, the full outcomes of the diverse actions of IL-6 in the retina have yet to be determined. Nevertheless, new treatment strategies are being developed towards targeting IL-6 as a potential treatment for diabetic retinopathy.
In the present study, we focused on characterizing expression and regulation of receptors that are associated with IL-6 signaling (mIL-6R, sIL-6R, gp130, and sgp130) and gaining more insight into the effects of IL-6 signaling on human Müller cells under hyperglycemic conditions. Human Müller cells play an important role in the development of diabetic retinopathy [[13], [14], [15], [16]]. They maintain the inner blood retinal barrier and are the only other retinal cell type besides photoreceptors found within the macula making them a strong candidate for promoting neovascularization as well as edema in the diabetic retina. They are also a well-known source for pro-inflammatory cytokines and VEGF-A production [13,17,18]. Therefore, the purpose of this study was to evaluate the ability of human Müller cells to signal through either classical IL-6 or IL-6 trans-signaling and to identify potential mechanisms of action for the protective effects of IL-6 on neuroretinal cells, such as Müller cells.
Section snippets
Antibodies and recombinant proteins
IL-6, IL-6/sIL-6R, VEGF-A, VEGFR inhibitor (Axitinib), human BD Fc Block, mouse anti-mIL-6R-APC antibody, and mouse anti-gp130-PE antibody were purchased from R&D Systems (Minneapolis, MN). Rabbit anti-mIL-6R and rabbit anti-gp130 antibodies were obtained from Abcam (Cambridge, MA). Anti-rabbit Texas Red antibody was purchased from Invitrogen (Carlsbad, CA). Human Milliplex MAP magnetic bead panels were purchased from MilliporeSigma (Burlington, MA).
Tissue culture of human retinal Müller cells
Handling of human tissue conformed to the
Determination of mIL-6R and gp130 levels on human Müller cells
Human Müller cells (HMCs) express the membrane bound form of the IL-6 receptor (mIL-6R) and the co-receptor gp130 under normal glucose conditions. Two methods were used to determine expression of mIL-6R and gp130, immunohistochemistry and flow cytometry. Fig. 1A and C shows that HMCs express mIL-6R and gp130 as demonstrated by immunofluorescence. Interestingly, some of the gp130 seems to be located around or within the nucleus. The expression levels of mIL-6R and gp130 were also verified using
Discussion
The primary objective of the present study was to determine the effects of IL-6 on human retinal Müller cells. This is the first study looking in detail at consequences of the activation of the two distinct IL-6 signaling pathways, classical IL-6 signaling versus IL-6 trans-signaling, under normal and hyperglycemic conditions in human Müller cells, which are hugely important for the development of diabetic retinopathy. The major findings of our study are that human Müller cells strongly respond
Conflicts of interest
BAC, BTT, and SM have no financial disclosures that would be potential conflicts of interests with this manuscript.
Acknowledgement
This project was supported by DFI (Discretionary Funding Initiative; SM) funding from Michigan State University and grant NIFA MICL02375 (SM).
References (24)
- et al.
IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer
Cytokine Growth Factor Rev.
(2011) - et al.
Inhibition of interleukin-6 trans-signaling prevents inflammation and endothelial barrier disruption in retinal endothelial cells
Exp. Eye Res.
(2019) - et al.
Inhibition of interleukin-6 trans-signaling prevents inflammation and endothelial barrier disruption in retinal endothelial cells
Exp. Eye Res.
(2019) - et al.
Müller cells and diabetic retinopathy
Vis. Res.
(2017) - et al.
Müller cells in the healthy and diseased retina
Prog. Retin. Eye Res.
(2006) - et al.
siah-1 protein is necessary for high glucose-induced glyceraldehyde-3-phosphate dehydrogenase nuclear accumulation and cell death in müller cells
J. Biol. Chem.
(2010) VEGF production and signaling in Müller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases
Vis. Res.
(2017)Anti-Vegf Treatments
(2019)Interleukin-6: discovery of a pleiotropic cytokine
Arthritis Res. Ther.
(2006)- et al.
The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis
Int. J. Rheumatol.
(2011)
IL-6 in inflammation, immunity, and disease
Cold Spring Harb. Perspect. Biol.
Interleukin-6 as a photoreceptor neuroprotectant in an experimental model of retinal detachment
IOVS (Investig. Ophthalmol. Vis. Sci.)
Cited by (14)
The innate immune system in diabetic retinopathy
2021, Progress in Retinal and Eye ResearchCitation Excerpt :Therefore, although systemically produced IL-6 is known to be capable of crossing the blood-brain barrier as an acute phase reactant, its elevation in the retina is most likely from secretion by retinal immune-competent cells. In vitro evidence suggests that IL-6 protects Müller cells from hyperglycemia via a VEGF-dependent mechanism (Coughlin et al., 2019); this may help to explain why steroids are neuroprotective but detrimental to Müller cells (Pereiro et al., 2018). This aligns with the finding that IL-6 reprograms Müller cells for retinal regeneration in zebrafish; however, IL-6 has also been implicated in contributing to choroidal neovascularization (Izumi-Nagai et al., 2007; Zhao et al., 2014).
Diabetic Müller-Glial-Cell-Specific Il6ra Knockout Mice Exhibit Accelerated Retinal Functional Decline and Thinning of the Inner Nuclear Layer
2023, Investigative Ophthalmology and Visual ScienceThree Major Causes of Metabolic Retinal Degenerations and Three Ways to Avoid Them
2023, International Journal of Molecular SciencesRole of interleukin - 6 in ocular inflammatory diseases
2023, International Eye ScienceResults and insights from a phase I clinical trial of Lomecel-B for Alzheimer's disease
2023, Alzheimer's and DementiaThe role of retinal Müller cells in diabetic retinopathy and related therapeutic advances
2022, Frontiers in Cell and Developmental Biology